USPTO serial 79204968
VECTURA V
Reviewed by CopyMark Law Group
Reg. 5398606Status 709
- Filing date
- Status date
- Registration date
- Feb 13, 2018
- Examiner
- MARTIN, CHRISTINE C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with VECTURA V?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Molly B. Markley
Molly B. Markley Young Basile Hanlon & MacFarlane P.C.3001 West Big Beaver RoadSuite 624Troy, MI 48084-3107Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical and biological preparations for medical purposes, namely for the treatment of diseases or conditions of the respiratory system; pharmaceutical and biological preparations for medical purposes, namely the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynaecological conditions; pharmaceutical and biological preparations for medical purposes, namely for the alleviation or prevention of pain or inflammation; pharmaceutical and biological preparations for medical purposes, namely, powders for asthma inhalers; pharmaceutical and biological preparations for medical purposes, namely, powders for transdermal injection for the alleviation or prevention of pain, for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for oral ingestion for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genitourinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purposes, namely for topical administration for the treatment of diseases or conditions of the respiratory system, diseases or conditions of the cardiovascular system, diabetes, cancer, arthritis, diseases or conditions of the gastro-intestinal system, diseases or conditions of the central nervous system, diseases or conditions of the endocrine system, diseases or conditions of the genito-urinary system, infections, skin disorders and gynecological conditions; pharmaceutical and biological preparations for medical purpose, namely, medicaments for inhalation therapy; pharmaceutical and biological preparations for medical purposes, namely, pulmonary delivery compositions for use in facilitating the inhalation of pharmaceuticals, namely, drug delivery agents consisting of compounds that facilitate delivery by inhalation of a wide range of pharmaceuticals; pharmaceutical and biological preparations for medical purpose, namely medicaments for the treatment of erectile dysfunction, medicaments for the treatment of chronic obstructive pulmonary disease, medicaments for the treatment of premature ejaculation, medicaments for the treatment of cystic fibrosis, medicaments for the treatment of female sexual dysfunction, medicaments for the treatment of migraines, medicaments for the treatment of asthma | SECTION 71 - CANCELLED | — |
| 010 | Medical apparatus and instruments, namely drug delivery devices, namely drug delivery systems; inhalers for medical use; metered dose inhalers for medical use; active dry powder inhalers for medical use; passive dry powder inhalers for medical use; nebulisers for respiration therapy; respirators for artificial respiration; parts and fittings for all the aforesaid goods | SECTION 71 - CANCELLED | — |
| 042 | Scientific research, development, design, analysis, testing and investigation relating to medical preparations and drug delivery devices; medical research; research relating to drug delivery devices; research relating to drug formulation; pharmaceutical development; preparation and formulation of pharmaceuticals; device and product testing | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks owned by Vectura Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Similar marks named VECTURA V
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 15, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 27, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Sep 5, 2025 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Aug 16, 2025 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Aug 16, 2025 | INPC | INVALIDATION PROCESSED | — |
| Apr 30, 2025 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 30, 2024 | C71T | CANCELLED SECTION 71 | — |
| Dec 22, 2023 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Feb 13, 2023 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Oct 8, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jul 13, 2018 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 23, 2018 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 23, 2018 | FIMP | FINAL DISPOSITION PROCESSED | — |
| May 13, 2018 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 13, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 8, 2017 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Nov 28, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 28, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 22, 2017 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Nov 22, 2017 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Nov 8, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Oct 20, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 11, 2017 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 11, 2017 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 11, 2017 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 13, 2017 | RFNT | REFUSAL PROCESSED BY IB | — |
| Apr 25, 2017 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Apr 24, 2017 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Apr 20, 2017 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Apr 19, 2017 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 18, 2017 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 14, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 14, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 13, 2017 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |